Ämnen: Haelso-sjukvaard
-
First half of 2006: Sales growth of 7.7% on a reported basis and 4.5% on a comparable basis1 Adjusted EPS1 growth of 32.9%, or 16.1% excluding selected items3
-
Results 1st half 2006
-
Sanofi-aventis responds to the emergency request for humanitarian aid to Lebanon
-
TAXOTERE® RECEIVES POSITIVE OPINION
-
TAXOTERE® RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER
-
Agreement between sanofi-aventis and Roche
-
STUDY ANALYZES GENE THERAPY FOR PATIENTS AT HIGH RISK FOR AMPUTATION
-
CHARISMA: NEW STUDY FURTHERS UNDERSTANDING OF THE ROLE OF DUAL ANTIPLATELET THERAPY IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS
-
Apidra ® A New Rapid-Acting Insulin Analog is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
-
RESCHEDULING OF THE TRIAL DATE IN THE UNITED STATES PLAVIX® LITIGATION
-
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION PUBLISHES THE RIO-NORTH AMERICA STUDY
-
SANOFI PASTEUR DELIVERS MORE H5N1 VACCINE FOR U.S. GOVERNMENT PANDEMIC INITIATIVES
Visa mer
Loading...